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ABSTRACT 
 
This thesis is composed of two different projects, both dealing with the 
synthesis part of drug development.  
 
The first project is in the subject of organometallic chemistry and deals 
with method development for the synthesis of substances that could 
be used in estrogen replacement therapy. It presents the successful 
use of CuO as co-reagent in various Stille couplings of sterically 
hindered bi- and heterobiaryls, meant to function as mimetics of the 
estradiol backbone. The results clearly point to the advantages of the 
method compared to the classical Stille cross-coupling methodology for 
this kind of reactions. 
 
The second project covers the synthesis of ligands designed to bind to 
the A-peptide and keep it in -helical form. These new synthesized 
ligands are peptoids consisting of four building block units. Synthesis 
of peptoids was evaluated both in solution and on solid phase. Several 
new building blocks for peptoids were synthesized including the new 
amino acid N-(2-aminoethyl)-2,4-diaminobutanoic acid. The new 
ligands will be evaluated with respect to A helix stabilisation and 
subsequent biological assays. 
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 LIST OF ABBREVIATIONS 
 
A  amyloid -peptide 
 
AD  Alzheimer’s disease 
 
Boc  tert-butoxycarbonyl 
 
CH2Cl2            dichloromethane 
 
CHCl3  chloroform 
 
Cbz               carbonylbenzyloxy 
 
DBU              1,8-diazobicyclo[5,4,0]- 
                     undec-7-ene 
 
DIPEA           diisopropylethylamine 
 
DMAP            dimethylaminopyridine 
 
DMF  N, N-dimethylformamide 
 
 
DMSO           dimethylsulphoxide 
 
EDT               ethanedithiol 
 
ES-TOF          electron spray – time of         
.                    flight (mass spectrometry) 
 
Fmoc  fluorenylmethyloxycarbonyl 
 
HATU            (2-(7-aza-1H-benzotriazole-
1-yl)-1,1,3,3-tetramethyl-
uronium hexafluoro 
phosphate 
 
HBTU             2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium 
hexafluorophosphate 
 
HOAc            acetic acid 
 
HPLC             High performance liquid 
                    chromatography                    
 
MeOH            methanol  
 
MS           mass spectrometry 
 
NMM  N-methylmorpholine 
 
NMR  nuclear magnetic resonance 
 
OBn  bensyloxy 
 
Pfp  pentafluorophenyl 
 
Pbf                2,2,4,6,7-pentamethyldi-  
                    hydrobenzofuran-5-sulfonyl 
 
RP-HPLC       reverse phase - HPLC 
 
Succ  succinyl 
 
TFA               trifluoroacetic acid 
 
THF               tetrahydrofuran 
 
TIS               triisopropylsilane 
 
TLC               thin layer chromatography 
 
 
Amino acids used 
(natural and non natural) 
 
Arg               arginine 
 
Dab               2,4-diaminobutanoic acid 
 
Dap               2,4-diaminopropanoic acid 
 
Glu  glutamic acid 
 
Gla  glutaric acid 
 
Lys                lysine 
 
Orn               ornithine  
 
Trp                tryptophane  
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 Method development for synthesis of   Estradiol mimics 
 
Background  
Biology 
Estrogen is a collective name for a group of steroid compounds, named for 
their importance in the estrous cycle. It consists of estriol, estrone and 
estradiol (Figure 1). Out of these, estradiol is the predominant form in non-
pregnant females. Estrogens play an important role in reproductive, skeletal, 
cardiovascular, and central nervous system function in both males and 
females. 
 
             
 
Estrone        Estradiol   Estriol 
 
Figure 1. Estrogens 
 
Post-menopause estrogen production decrease is associated with several 
pathological processes like osteoporosis, coronary heart disease and 
Alzheimer’s disease. These diseases are usually treated by replacing the loss 
of the bodies own estrogen production with exogenous estrogen, so called 
estrogen replacement therapy (ERT). However, although ERT replaces lost 
estrogen levels, it may also cause breast cancer. 1 Therefore it is important 
to find alternative compounds that stimulate estrogen action only in target 
organs, certain cell types or in receptor isoforms. These properties are found 
in selective estrogen receptor modulators (SERM’s).  
SERM’s act as agonists in tissues where it is needed, like for instance in bone 
tissue, while at the same time as antagonists in such tissues like uterus, 
breast and brain. In this way they can arrest osteoporosis by stimulating 
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 continued bone turnover while, for example, simultaneously inhibiting cancer 
progression in uterus and breast tissue.2 Although fairly effective in arresting  
side effects, even SERM’s have been shown to be a source of side effects like 
thrombosis1 and increases in endometrial and breast cancer. Many SERM’s 
also, suffer from low bioavailability, they are not absorbed very well by the 
body and well in the system they are quickly metabolized and lose most of 
their effect.1 Therefore it is of importance to continue drug discovery in this 
field. 
 
Chemistry 
It has been observed that a wide variety of compounds can exhibit estrogenic 
activity, e.g. the naturally occurring phytoestrogens and various synthetic 
xenoestrogens. In a study of polychlorinated biphenyls (PCB’s) by Korach in 
19883, it was found that most of them showed estrogenic activity. The ones 
with the highest activity were the conformationally restricted 4’-hydroxy 
PCB’s, which are those with one or two chlorines ortho to the biphenyl bridge 
(Figure 2). LeSuisse et al, 13 years later, synthesized several analogues to 
these using the Suzuki4, Negishi4 and Ullman5 couplings with several 
variations.6 Yields were low, especially when the halogen cross-coupling 
partner was substituted at both ortho positions.3 A viable alternative for the 
assembly of sterically hindered biaryls in reasonable yields was to use CuO as 
co-reagent, as described by the Salo Gronowitz group.7  
S OH
O
HO
O
N
Cl
Cl
Cln
HO
 
Di-ortho-substituted PCB   Raloxifen 
Figure 2. Xenoestrogens. 
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 The couplings 
The Suzuki coupling has emerged as the most common coupling for the 
preparation of biaryl compounds during the last decade, partially due to the 
inherent toxic properties of organotin reagents used in the alternative Stille 
coupling. In Scheme 1 below, the Suzuki and the Stille couplings are shown. 
The Suzuki-coupling uses boronic acids and aryl halogens as coupling 
partners, while the Stille coupling uses stannanes and aryl halogens. 
Furthermore, it can be noted that the Stille-coupling requires no protection 
for its phenol moiety, as the reaction conditions for the Stille coupling are 
non-aqueous and neutral. Protection could therefore be crucial for the Suzuki 
coupling. 
Suzuki coupling
O Br (HO)2B
Pd(Ph3P)4
base, DMF
O+
Stille coupling
HO Br Me3Sn
Pd(Ph3P4
     DMF
HO+
 
Scheme 1. Comparison of reaction conditions used in the Suzuki coupling and the 
Stille coupling respectively. 
 
Initial studies in synthesis of aryl thiophene backbones with Suzuki coupling 
gave poor results (unpublished data) and in light of this we decided to 
investigate the feasibility of the Stille coupling for the synthesis of estradiol 
mimetics. Stannanes also have longer shelf life than its boronic acid 
counterparts. Organotin compounds can be toxic, both for man and nature, 
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 but since Renaud et al’s report 19988, we now know that all traces of tin in a 
reaction mixture can be completely removed upon work-up in the presence 
of Et3Al or NaOH (aq).  
 
The Stille cross-coupling reaction is a palladium–catalyzed reaction. The use 
of palladium as a catalyst means that it is recycled as depicted in Scheme 2 
below. 
 
PdL4
Pd0
Ar-X
Ar-PdII-X
oxidative addition
Ar'-SnMe3
XSnMe3
Ar-PdII-Ar'
transmetallation
Ar-Ar'
reductive elimination
 
 
Scheme 2. Palladium-catalyzed Stille cross-coupling reaction. 
 
A range of metal salts and oxides have been added to the reaction as co-
reagents in order to see whether they could catalyze the reaction and a few 
have stood out more than others.7b CuO gave the best results catalyzing 
cross-couplings of sterically hindered reaction partners. 
 
The mechanistic role of CuO is still uncertain. We can only note that sluggish 
Stille cross-coupling reactions can be accelerated by CuO addition, and that it 
is generally accepted that the rate determining step is the transmetallation 
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 step. What this means mechanistically still needs more research to say for 
certain. 
As a conclusive assessment of the role of Cu has yet to be made, one can 
only say that even though 18 years have passed since the discovery of the 
accelerating effect of amphoteric oxides as CuO and Ag2O in the Stille-
coupling, no viable mechanism can still explain its effect.    
 
Ligandless palladium 
We also wanted to try to run our reactions using another palladium strategy, 
namely “ligandless” palladium,9, 10 as it has been reported to show good 
yields in systems similar to our own. Ligandless palladium means adding a 
palladium species with more loosely complexed ligands and then exchanging 
those ligands in situ with another type of ligand. Several types of palladium-
ligand complexes were considered, but the one that seemed best suited for 
our reaction was the loosely complexed palladium species 
tris(benzylideneacetone)dipalladium (Pd2dba3) and as the ligand exchanged 
for trifurylphosphine was chosen (Figure 3), as it reportedly had produced 
good yields in reaction conditions similar to ours.11 Also, our group has 
previously attempted using the more loosely binding ligand AsPh3 in similar 
reactions without success.7d 
 
O
O
O
Pd
Pd
Ph
Ph
Ph
Ph
Ph
Ph
O
P
O
O
 
 
Figure 3. Tris(benzylideneacetone)dipalladium (Pd2dba3) and trifuryl-phosphine, 
respectively. 
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 Results and discussion 
 
In our paper “Synthesis of estradiol backbone mimetics via the Stille reaction 
using copper(II) oxide as co-reagent”12 we have evaluated the use of CuO as 
co-reagent in the synthesis of xenoestrogen backbones based on hindered 
biphenyls and aryl thiophenes. First attempts were made to synthesize a 
starting building block for Raloxifen by coupling 2-trimethylstannyl-6-
methoxybenzo[b] thiophene with substituted phenyl bromides. The reactions 
were made as follows (Method A): the stannane was added via a syringe to a 
stirred mixture of the appropriate bromophenol in DMF containing 
tetrakis(triphenylphosphine) palladium(0) (5 mol%), and with or without the 
presence of CuO (equimolar amounts). Prior to stannane addition, the 
mixture had been purged with argon for 15 minutes. The reactions were 
heated at 95-100 °C over night.  
  
 
 
 
 
MeO S
SnMe3
R1
Br
R3
Me
R2
MeO S
Me
R3
R1
R2
+
Pd(0)
Entry 
 
 
R1 R2 R3 Yield 
without 
CuO (%)a 
 
Yield  
with CuO 
(%)a 
 
1 H H H n.d. 98 
2 
 
H H Me 0 61 
3 
 
OH H Me 0 37 
4 
 
OH Me H n.d. 46 
 
Table 1. Palladium-catalyzed cross-coupling of 2-trimethylstannyl-6-
methoxybenzo[b]thiophene with aryl bromides. a Yields refer to isolated products. 
n.d. = not determined. 
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 As can be seen, the presence of CuO was mandatory in order to obtain the 
desired product (entries 2 and 3). Yields were lower when the R1-position 
was substituted with a hydroxyl group.  
 
Boronic acids (Suzuki coupling) were also evaluated as coupling partners 
using a wide variety of conditions, but resulted in complex reaction mixtures 
and low yields of the desired products (unpublished data).  
 
Next, we wished to investigate the formation of a similar kind of 
estrogenically active compounds, sterically hindered biaryls, 4-(1’-hydroxy-
3’,5’-dimethylphenyl)-benzaldehyde, with and without benzyl protection of 
the phenolic hydroxyl group (Table 2). The presence of the R2-formyl group 
represents the synthetic precursor of the hydroxymethyl group in the 
estradiol mimetic shown in Figure 2. These reactions were performed both in 
the absence and in the presence of CuO (Table 2) under conditions identical 
to those for the aryl thiophene derivatives. The reactions were allowed to run 
until no further development could be observed (as seen by TLC). The 
reaction mixture was then refluxed with ethyl acetate and activated carbon, 
filtered, evaporated and analyzed by HPLC. The results from these reactions 
are shown below (Table 2), conversions were determined by HPLC using an 
internal standard13. 
 
For this second kind of biaryl, an alternative to the stronger binding 
triphenylphosphine palladium ligands of the first method was also to be 
evaluated in the cross-coupling. These reactions were run under ligandless 
conditions (Method B): 4-trimethyl-stannylbenzaldehyde was added to a 
reaction mixture of the bromide and Pd2Dba3 (5 mol%) and trifurylphosphine 
in DMF  with heating set to 65°C (the mixture had been purged with argon 
prior to the bromide addition). The “ligandless”  reactions were evaluated as 
stated for the reactions with the tetrakis(triphenylphosphine) ligands.   
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 R1
Br
Me
Me
R2
Me3Sn
R1
R2
Me
Me
+
"Pd"
 
 
Entry R1 R2 Method  Reaction 
time, h a 
Yield, % a 
1 OH CHO A 20 (102) 94, 80 b (51) 
2 OBn CHO A 18 (23) 47 (45) 
3 OH CHO B 69 (30) 25 (5) 
4 OBn CHO B 96 (50) 8 (9) 
5 OH COOH A 28 (20) n.d. (n.d.)c 
 
Table 2.  Palladium-catalyzed cross-coupling of arylstannanes with arylbromides.   
a Yields refer to conversions determined by HPLC analysis (unless otherwise stated) 
and yields and reaction times in brackets refer to runs without CuO. b Isolated yield 
in a separate synthesis. c reactions gave complex mixtures and the desired product 
was not isolated or identified. n.d. = not determined. 
 
The first observation is that also in the couplings with benzaldehyde stannane 
(using Method A), addition of CuO results in better yields and shorter 
reaction times. Although, with the benzyl protected bromophenols there was 
virtually no effect of CuO addition. The reason for running the coupling 
reactions under argon atmosphere was that the benzaldehyde stannane 
turned out to be extremely sensitive to air oxidation. Merely leaving the 
benzaldehyde stannane exposed to air was enough to oxidize it completely in 
a couple of weeks. After this discovery we found ourselves in the possession 
of the corresponding benzoic acid stannane and it was natural to include it in 
our study. However, the reaction with this substrate turned out to result in 
complex mixtures. 
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 For the runs employing ligandless conditions the yields from the couplings in 
were considerably lower, compared to those from Method A, irrespective of 
use of a protected or unprotected phenolic function of the stannane cross-
coupling partner. However, just like in Method A, yields were higher in the 
presence of CuO in the reaction with the unprotected phenol as cross-
coupling partner. As opposed to with Method A the reaction times were 
higher when CuO was used as co-reagent.  
 
Comparing the two methods, a few observations can be made. For the biaryl 
couplings, the use of stronger binding ligands (Method A) was clearly the 
better alternative, irrespective of whether CuO was used as co-reagent or 
not. The palladium-catalyzed cross-coupling, was considerably more effective 
in combination with CuO than without (Tables 1 and 2) when an unprotected 
bromophenol was used. It resulted in higher yields as well as a substantially 
shorter reaction time in the reaction with the unprotected phenol (Table 2, 
entry 1), and with the benzothiophenes there was no detectable product 
whatsoever without CuO-addition. When a protected phenol (-OBn) was used 
as the coupling partner, CuO-addition did not give much improvement (entry 
2, Table 2). Ligandless conditions (Method B) gave quite inefficient cross-
coupling of these substances, for both unprotected and protected phenols 
(Table 2, entries 3 and 4), both with and without CuO. 
 
 
Conclusion 
 
In summary, we have shown that the Stille palladium-catalyzed cross-
coupling of benzothiophene and benzaldehyde stannanes with bromophenols 
is greatly improved when the co-reagent CuO is used. Comparing the two 
Methods A and B, also suggests the use of tetrakis(triphenylphosphine) 
palladium(0) rather than “ligandless” conditions for Stille cross-coupling 
reactions of hindered biaryls.  
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 Peptoid ligands for the Alzheimer A-peptide 
 
Background  
Biology 
Many diseases are caused by misfolded peptides and proteins, despite the 
many control mechanisms nature provides to insure proper folding.14 Around 
40 (and increasing) diseases are associated with the misfolding and 
aggregation of proteins and peptides into structures known as amyloid 
fibrils.15 This group includes, for example, the neurodegenerative 
Alzheimer´s, Parkinson´s and Creutzfeld-Jacob´s diseases.16  
 
Alzheimer’s disease (AD) is a progressive brain disorder that gradually 
destroys a person’s memory and ability to learn, reason, make judgments, 
communicate and carry out daily activities. It is the most common cause of 
dementia, accounting for about 60% of the cases17 and has historically been 
strongly associated with amyloid plaque. Amyloid plaques are composed of 
amyloid fibrils assembled into disordered networks, and the amyloid fibrils, in 
turn, are composed of polypeptide chains in -strand confirmation, which 
form -sheets running perpendicular to the long axis of the fibril. These 
structures share the same morphology regardless of what peptide they are 
formed from. They are also protease resistant and the organism is unable to 
degrade them to any significant extent. 
 
Previously it was thought that the Alzheimers diseases related amyloid 
plaques in brain caused the neurotoxicity. There is, however, increasing 
evidence that the neurotoxicity is mainly caused by soluble intermediates or 
even by the aggregation process.18  
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Figure 3. Protein folding and misfolding. A-peptide in its various forms, from 
unfolded to amyloid fibrils. (Fibril model adapted from Jimenez et al., 
1999) 
 
It should be mentioned that amyloid plaques in general are not only 
pathological in nature. They can also be a part of a wide range of natural 
functions in living organisms.19 
 
In the case of Alzheimer’s disease, amyloid plack and all intermediates are 
mainly formed from the same building block, namely the amyloid- peptide 
(A-peptide). This is a part of a transmembrane peptide called amyloid- 
precursor protein (APP). APP is expressed in a large variety of cell types 
throughout the body and has no known function.23c 
 
The A-peptide is formed as parts of APP are cleaved off. First a large 
segment of APP is cleaved off, leaving one part on the outside and the other 
on the inside of the membrane. 
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Figure 4. Formation of A. 
 
After -secretase has cleaved off APPs, A is positioned partly in the 
membrane and partly on the outside as depicted in Figure 5 below. As can 
be seen, the A-peptide harbours two -helices, one in the membrane and 
one directly outside the membrane.  
 
 
 
 
 
Figure 5. A-peptide after -secretase has cleaved off the outermost segment. 
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 The resulting peptide is cleaved once more, this time by -secretase, forming 
the A-peptide. When departing from the membrane it loses its helical 
conformation and turns into other forms with toxic properties, either as a 
soluble monomer of various conformations, or forming soluble oligomers or 
aggregates of these (see above, Picture 3).  
 
The Apeptide contains a discordant helix (residue 16-23) i.e. a helix 
composed of amino acids with a high propensity for -strand conformation. 
Peptides derived from this discordant helix region form fibrils and, in A, this 
region has been found essential for fibril formation20 The aggregation process 
of A is not fully understood and it is unclear which forms of A that are 
toxic. Early aggregates are not structurally defined, making inhibitor design a 
difficult task and it is also possible that targeting species on the fibrillation 
pathway may result in accumulation of toxic oligomers. A more appealing 
idea would be to target and stabilize an A-monomer, thereby preventing 
misfolding and subsequent amyloid formation.  
 
We have previously shown that by using small designed ligands, directed 
towards the discordant region of Aresidues 13-23), it is possible to stabilize 
the helical structure of a freshly cleaved off A-peptide, thereby reducing 
aggregation in vitro. 21 These ligands also reduced cell toxicity of A and 
prevented A induced reduction of  oscillations of hippocampal slices. 
Gamma oscillations play an important role in higher processes in the brain, 
such as learning, memory, cognition, and perception22 and are markedly 
reduced in patients diagnosed with Alzheimer’s disease23  
In addition, oral administration of two of these compounds in the Drosophila 
model of Alzheimer’s disease24 increases longevity, decreases locomotor 
dysfunction and reduces neuronal damage25 Altogether, these results are 
promising and suggest that this concept is worth pursuing and may lead to 
an effective Alzheimer’s treatment. 
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 Chemistry 
To further test our hypothesis and to develop ligands with higher affinity to 
the Aβ region covering residues 13-23, several new peptoid ligands designed 
to bind and stabilize the Alzheimer’s disease related amyloid -peptide in -
helical conformation were synthesized. In addition, we explored different 
methodologies to diversify the synthesis of potential ligands. 
 
Peptide synthesis 
Peptide synthesis in solution phase is commonly used and sometimes still 
preferred, but it is often tedious and time consuming, especially when longer 
peptides are to be made. Already in 1963, Bruce Merrifield reported 
successfully having synthesized a peptide employing a solid phase scheme. 
He had attached the starting amino acids to small polystyrene beads, and 
then in a stepwise fashion coupled further amino acids, forming a peptide 
that was subsequently cleaved off and isolated. This was no less than a 
revolution in peptide synthesis as it greatly could improve synthesis of longer 
peptides and in the same time introduced a protocol that could be robotized. 
The protocol (Scheme 3) begins with the swelling of the resin in order to 
open up the pores, thereby increasing the surface available. The starting 
amino acid is attached to the resin, after which it is washed and deprotected. 
The amino acid to be attached, either has an activated carboxyl group or a 
condensing agent, like the today most commonly used HBTU or HATU 
reagents (Figure 6), for the coupling. The deprotection of a previously 
blocked amino group, leaves it ready to couple to the next amino acid. This 
cycle is then repeated, starting with the coupling of the next amino acid. 
When all amino acids have been coupled, the resulting peptide is cleaved off 
from the resin and isolated.  
An advantage of solid phase peptide synthesis is that all the time consuming 
isolation steps between couplings can be cut out. Solid phase peptide 
synthesis usually follows a standardized protocol (exemplified in Scheme 3). 
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Scheme 3. Solid phase peptide synthesis. 
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 Commonly all functionalities of the amino acids that could disturb the 
reaction are blocked by protecting groups. With several active groups on the 
amino acids, protecting groups play a central role in the synthesis of peptides 
and peptoids. Today there exists a great amount of various protective groups 
for all the side chain functionalities that has to be blocked from taking part in 
a reaction, when they are not meant to. Also it is important to be able to 
selectively cleave only certain protecting groups and when there are many 
different functionalities that need protection, so called orthogonal protecting 
groups are useful. This means protecting groups that are cleaved in different 
conditions, to be able to selectively cleave the desired groups. Two of the 
most frequently used protecting groups are the Fmoc-group and the Boc-
group, standing for fluorenylmethyloxycarbonyl and t-butoxycarbonyl 
respectively (Figure 6).  
 
O
O
H
N
R
O
O
N
H
R
Fmoc Boc
N
N
N
NN
PF6
-
HBTU
HATU
O-
+
N N
N
N
NN
PF6
-
O-
+
 
 
Figure 6. Protecting groups and condensing agents. 
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 The Fmoc-group is easily cleaved off under basic conditions, using a 20% 
piperidine in DMF-solution, whereas the Boc-group is cleaved under acidic 
conditions (typically TFA containing solutions).  
 
 
Results and discussion 
 
Different peptoids for binding to and stabilizing A-peptide in -helical 
conformation were synthesized. Synthesis methods were evaluated and two 
peptoids were isolated from solution synthesis and one, containing a novel 
amino acid, was isolated from solid support synthesis. 
 
For the solution synthesis (Scheme 4), we started with the synthesis of the 
dipeptoid Orn(Trp) with the side chain amino group of ornithine forming the 
amide bond with tryptophane, instead of, as with peptides, the -amino 
group. We wanted to have this as a building block in order to avoid the risk 
of cyclization, which could occur after deprotection of the -amino Fmoc-
group of Orn following coupling to the diacid. Fmoc based synthesis of a 
peptoid where one intermediate is an esterified diaminobutyric acid (Dab) 
with a free -amino group, could potentially give intramolecular cyclisation 
which would truncate further couplings. 
 
In the first step the pentafluorophenyl ester of Fmoc-D-Trp (2) was coupled 
to the -amino group of Boc-D-Orn-OH to give 3. We then tried to make the 
t-butylester of 3, via a published methodology26 but yields were low, so it 
was instead protected as a benzyl ester (4) using benzyl bromide27 in good 
yield. The Fmoc group was then removed and the resulting compound 5 was 
coupled to Fmoc-Arg(Pbf)OPfp 6 to give 7 in 88% yield.  
 
In order to minimize side reactions on tryptophane while keeping the Pfp 
protection intact, we tried removal of the Boc group using BiCl3 in the 
presence of H2O.
28 The literature procedure gave 10% deprotection or less, 
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 but after alteration of the protocol (BiCl3 ~ 3 eq) the desired peptoid 8 was 
achieved in 51% yield. 8 was then coupled with either succinic anhydride or 
glutaric anhydride to give the desired peptoids 10a and 10b respectively. 
After removal of the benzyl group by catalytic hydrogenation using Pd/C, we 
arrived at 11a and 11b. This was followed by removing Fmoc (20% 
piperidine in DMF) giving 12a and 12b, and then the final deprotection by a 
TFA-based cocktail (Phenol: EDT: thioanisole: H2O: TFA), containing 
scavengers to minimize modification of Trp residues29 The desired product  
was however impure and hard to purify. Therefore we instead attempted 
deprotection of 12a and 12b using a TIS-TFA (Triisopropylsilane-phenol-
H2O-TFA) based cocktail30 This resulted in purer material and 13a and 13b 
could readily be isolated by semi preparative RP-HPLC. 
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 BocHN
OHO
FmocHN
OPfp
O
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N
HN
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OHO O
NH N
HFmoc
Boc
PfpO
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O
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NHHN
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+
+
4 5
6 7
Na2B4O7 (aq) pH  8.5
    DMF, 0 oC - r.t.
KHCO3, TBAI, BnBr
    DMSO, r. t.
20% Piperidine in DMF
            r. t., 1h
Et3N, CH2Cl2, DMF 
        
            r. t.
1
 
Acetonitrile, H2O, BiCl3
         55 0C, 3h
 i) Succinic anhydride
 ii) Glutaric anhydride 
DMF / pyridine, r. t., 2h
           Pd/C
THF, MeOH, r. t., 1h
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OBn
O
O
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O
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NHHN
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Fmoc O
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O
O
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NH
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O
NH
NHHN
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O
HO
O
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N
H
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OHO O
NH
NH
O
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NHHN
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R2
R1
O
HO
O
R3
+
8
9a; R1= CH2CH2
9b; R1= CH2CH2CH2
11a (R1= CH2CH2) and 11b (R1=CH2CH2CH2): R2 = Fmoc, R3 = Pbf
12a (R1= CH2CH2) and 12b (R1=CH2CH2CH2): R2 = H, R3 = Pbf
13a (R1= CH2CH2) and 13b (R1=CH2CH2CH2): R2 = H, R3 = H
20% Piperidine in DMF, r. t., 1h
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Scheme 4. Solution phase synthesis of peptoids 13a and 13b. 
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 Synthesis of peptoids in solution is rather time consuming so we decided to 
investigate whether a solid support approach could be used. This way time 
consuming intermediate isolation steps could be completely omitted. It may 
be necessary to decrease the risk of cyclization of the Orn and Dab amino 
acids by attachment of a D-Trp-Orn/Dab dimer as one unit to the support. 
But it would also be interesting to see whether the feared cyclisation would 
be sufficiently slow to allow synthesis in a stepwise fashion. 
 
We also wanted to incorporate artificial triamino acids in the position 
occupied by arginine in the peptoid structures described above.  For this 
protected derivatives of N-(2-aminoethyl)diaminopropionic acid31 and the 
novel amino acid N-(2-aminoethyl)diaminobutyric acid were synthesized 
(Scheme 5). The central synthesis step for both non-natural amino acids, 
although carried out slightly differently for each one, was the coupling of 
diamino acid to N-Boc-glycinaldehyde, followed by reductive amination using 
NaCNBH3. The N
-(2-aminoethyl)diaminopropionic derivative 14 was 
synthesized by portionwise addition of NaCNBH3 to a chilled solution of 
methyl N2-benzyloxycarbonyl-2,3-diaminopropionic acid hydrochloride and 
N2-(tert-butoxycarbonyl)glycinal in 1% acetic acid in methanol. Subsequent 
Cbz-protection gave the ester 15, which was then hydrolyzed to 16 with 
LiOH. For the novel triamino acid derivative, N-(N-tert-butoxycarbonyl-2-
aminoethyl)-N-benzyloxycarbonyl-2,4-diaminobutanoic acid, the 
methodology used for the reductive amination was changed as we used the 
acid instead of the ester derivative. The solubility of the starting material was 
poor, even after addition of DMF, so the reaction was performed in an 
aqueous solution of Bu4NHSO4, resulting in 17. This derivative was then 
additionally Cbz-protected using benzyloxycarbonylsuccinimide to give 18. 
 
 28
 NOO
O
Ph
O
O
NaHCO3/H2O / dioxane,  0 - 5 
oC
O
OCbzHN
N
NH
Boc
Cbz
O
O
CbzHN
HN
NH
Boc
  LiOH (aq)
   MeOH
H
BocHN
O
CbzHN COOMe
H2N
+
NaCNBH3                                                     
1% HOAc / MeOH
14 15
 1) H2O - nBu4NHSO4 
 2) NaCNBH3
OH
O
CbzHN
N
NH
Boc
Cbz
16
H
BocHN
O
CbzHN COOH
H2N
+
OH
O
CbzHN
HN
NH
Boc
OH
O
CbzHN
CbzN
NH
Boc
NOO
O
Ph
O
O
NaHCO3/H2O / dioxane,  0 - 5 
oC
17 18  
 
Scheme 5. Synthesis of non-natural triamino acid building blocks 16 and 18. 
 
Before using the synthesized triamino acids in synthesis of peptoids, we 
decided to test an alternative route where, instead of using the synthesized 
bulding blocks in solid phase synthesis, the modified amino acid would 
instead be formed “in situ” on by performing the reductive amination on the 
support (Scheme 6). 
For this solid phase synthesis, the support (Wang polystyrene resin) was first 
reacted with succinic anhydride, then H-Lys(Fmoc)OMe was attached to the 
succinate support. Subsequent steps of Fmoc deprotection and coupling with 
D-Trp and then a diaminopropionic acid derivative were performed to give 
solid supported N-Succinyl-Lys-N-((N-Boc-N-Fmoc-Dap)-D-Trp)OMe. 
After removal of Fmoc from the side chain of Dap, the other part of the 
artificial amino acid was attached by reductive amination with N-Boc-glycinal 
and Na(OCOCH3)3BH. After cleavage from support, analysis of the crude 
material by MS showed that the desired product 19b had been obtained, but 
also that the main product was 19a which is the peptoid product expected if 
the reductive amination step failed. 
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Scheme 6. Attempted solid phase synthesis of tetrapeptoid 19b by reductive 
amination on support. 
 
Going back to our original thoughts, we decided to make a peptoid on solid 
support and to include the novel triamino acid building block 18 in the 
synthesis. This synthesis was initiated by functionalizing the Wang support 
with glutaric anhydride, which was in turn connected to Dab(Fmoc)OMe. 
After deprotection of the the -amino group of the Dab residue, Fmoc-
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 protected D-Trp was attached. The Fmoc on the D-Trp was then removed 
and the new triamino acid building block 18 was coupled to the -amino of 
the D-Trp residue using HATU as condensing agent. After cleavage from 
support by a TFA/TIS/Phenol cocktail and subsequent cleavage of the methyl 
esther by NaOH, the peptoid 20 containing the new amino acid N-
aminoethyl-2,4-diaminobutanoic acid could be isolated as the main product 
by RP-HPLC.  
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Scheme 4. Solid phase synthesis of tetrapeptoid 20 on Wang resin. 
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 CONCLUSION 
 
This project has produced several new potential ligands for stabilizing the -
helical conformation of the Alzheimer’s disease related A-peptide. The 
peptoid ligands were synthesized both by synthesis and on solid support. In 
addition a novel amino acid N-aminoethyl-2.4-diaminobutanoic acid has 
been synthesized and incorporated into one of these peptoids.  
 
Furthermore, a couple of solid phase procedures have been investigated. 
Reductive amination on support for attachment of the non-natural triamino 
acids was attempted, but was quite inefficient. Although the method could be 
optimized, it seems more reliable and straightforward to do the synthesis by 
attaching the triamino acids as one pre-prepared building-block. 
 
Our reactions did not seem to suffer much from the intramolecular cyclization 
reaction of the deprotected esterified diaminobutyric acid that we had initially 
feared. If it does happen during the synthesis, it is clearly slow enough to 
allow the coupling to proceed nearly unrestricted, to give the desired peptoid 
as the main product. We can not exclude that the cyclisation occurred to 
some extent, but it is clearly not a major problem. This opens up for more 
ready production of libraries where the different parts of the peptoid, that 
interact with the A-peptide, can be optimized. The synthesized peptoids as 
well as additional peptoids made by the solid phase approach will be 
investigated with respect to interaction with and retardation of aggregation of 
the A-peptide. 
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